Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. E...
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT05562466
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 56
- Registration Number
- NCT05519514
- Locations
- 🇮🇳
Study Site, Mangalore, India
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 110
- Registration Number
- NCT05509933
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis)
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT05444543
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
In Vivo Performance of Oral Liquid Formulations of Budesonide in the Fasted State in Healthy Subjects
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 12
- Registration Number
- NCT05429775
- Locations
- 🇬🇧
Sandoz Investigative Site, Nottingham, England, United Kingdom
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Amanda Stapleton
- Target Recruit Count
- 20
- Registration Number
- NCT04964414
- Locations
- 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Acupuncture Therapy for COVID-Related Olfactory Loss
- Conditions
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT04952389
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Replication of the D58 Asthma Trial in Healthcare Claims Data
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 66581
- Registration Number
- NCT04892732
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Shiraz University of Medical Sciences
- Target Recruit Count
- 66
- Registration Number
- NCT04561687
- Locations
- 🇮🇷
Shiraz University of Medical Science, Shiraz, Iran, Islamic Republic of
A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Intech Biopharm Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT04494321
- Locations
- 🇨🇳
Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.